흡입 일산화질소 시장 보고서 : 용도별, 지역별(2024-2032년)

The global inhaled nitric oxide market size reached US$ 943.7 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 1,657.7 Million by 2032, exhibiting a growth rate (CAGR) of 6.3% during 2024-2032.

Inhaled nitric oxide (iNO) refers to a selective pulmonary vasodilator supervised by skilled physicians at tertiary neonatal intensive care units (NICUs). It assists in regulating vascular muscle tone and treating hypoxemic respiratory failure among newly born infants by improving ventilation-perfusion mismatch and reducing elevated pulmonary vascular resistance and hypertension. It also aids in improving oxygenation and decreasing the need for extracorporeal membrane oxygenation (ECMO). At present, there is a rise in the use of iNO therapy as a rescue agent for acute respiratory distress syndrome (ARDS) patients.

Inhaled Nitric Oxide Market Trends:

The increasing prevalence of respiratory and other subsequent diseases in newborns, such as persistent pulmonary hypertension and neonatal hypoxic respiratory failure (HRF), represents one of the primary factors significantly contributing to the market growth. Additionally, the rising geriatric population, which is relatively more prone to hypertension, atherosclerosis, peripheral artery disease, heart failure, and thrombosis, is supporting the growth of the market. Furthermore, iNO is gaining immense traction worldwide for treating chronic obstructive pulmonary diseases (COPD), asthma, and ARDS. Moreover, the outbreak of the highly contagious coronavirus disease (COVID-19) and an alarmingly increasing number of individuals getting infected on a global level are favorably influencing the market. Furthermore, iNO therapy is being used against coronavirus stains as it assists in improving ventilation/perfusion in patients with severe pneumonia. The market is also driven by the ongoing research and development (R&D) activities in the healthcare industry around the world to improve the overall patient experience.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global inhaled nitric oxide market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on application.

Breakup by Application:

Neonatal Respiratory Treatment

Chronic Obstructive Pulmonary Disease (COPD)

Acute Respiratory Distress Syndrome (ARDS)

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Air Liquide S.A, Bellerophon Therapeutics, Beyond Air Inc., Linde plc, Mallinckrodt plc, Merck KGaA, Novoteris LLC, Nu-Med Plus and VERO Biotech LLC.

Key Questions Answered in This Report:

• How has the global inhaled nitric oxide market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global inhaled nitric oxide market?
• What are the key regional markets?
• What is the breakup of the market based on the application?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global inhaled nitric oxide market and who are the key players?
• What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Inhaled Nitric Oxide Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Application

• 6.1 Neonatal Respiratory Treatment
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Chronic Obstructive Pulmonary Disease (COPD)
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Acute Respiratory Distress Syndrome (ARDS)
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Others
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast

7 Market Breakup by Region

• 7.1 North America
  • 7.1.1 United States
    • 7.1.1.1 Market Trends
    • 7.1.1.2 Market Forecast
  • 7.1.2 Canada
    • 7.1.2.1 Market Trends
    • 7.1.2.2 Market Forecast
• 7.2 Asia-Pacific
  • 7.2.1 China
    • 7.2.1.1 Market Trends
    • 7.2.1.2 Market Forecast
  • 7.2.2 Japan
    • 7.2.2.1 Market Trends
    • 7.2.2.2 Market Forecast
  • 7.2.3 India
    • 7.2.3.1 Market Trends
    • 7.2.3.2 Market Forecast
  • 7.2.4 South Korea
    • 7.2.4.1 Market Trends
    • 7.2.4.2 Market Forecast
  • 7.2.5 Australia
    • 7.2.5.1 Market Trends
    • 7.2.5.2 Market Forecast
  • 7.2.6 Indonesia
    • 7.2.6.1 Market Trends
    • 7.2.6.2 Market Forecast
  • 7.2.7 Others
    • 7.2.7.1 Market Trends
    • 7.2.7.2 Market Forecast
• 7.3 Europe
  • 7.3.1 Germany
    • 7.3.1.1 Market Trends
    • 7.3.1.2 Market Forecast
  • 7.3.2 France
    • 7.3.2.1 Market Trends
    • 7.3.2.2 Market Forecast
  • 7.3.3 United Kingdom
    • 7.3.3.1 Market Trends
    • 7.3.3.2 Market Forecast
  • 7.3.4 Italy
    • 7.3.4.1 Market Trends
    • 7.3.4.2 Market Forecast
  • 7.3.5 Spain
    • 7.3.5.1 Market Trends
    • 7.3.5.2 Market Forecast
  • 7.3.6 Russia
    • 7.3.6.1 Market Trends
    • 7.3.6.2 Market Forecast
  • 7.3.7 Others
    • 7.3.7.1 Market Trends
    • 7.3.7.2 Market Forecast
• 7.4 Latin America
  • 7.4.1 Brazil
    • 7.4.1.1 Market Trends
    • 7.4.1.2 Market Forecast
  • 7.4.2 Mexico
    • 7.4.2.1 Market Trends
    • 7.4.2.2 Market Forecast
  • 7.4.3 Others
    • 7.4.3.1 Market Trends
    • 7.4.3.2 Market Forecast
• 7.5 Middle East and Africa
  • 7.5.1 Market Trends
  • 7.5.2 Market Breakup by Country
  • 7.5.3 Market Forecast

8 SWOT Analysis

• 8.1 Overview
• 8.2 Strengths
• 8.3 Weaknesses
• 8.4 Opportunities
• 8.5 Threats

9 Value Chain Analysis

10 Porters Five Forces Analysis

• 10.1 Overview
• 10.2 Bargaining Power of Buyers
• 10.3 Bargaining Power of Suppliers
• 10.4 Degree of Competition
• 10.5 Threat of New Entrants
• 10.6 Threat of Substitutes

11 Price Analysis

12 Competitive Landscape

• 12.1 Market Structure
• 12.2 Key Players
• 12.3 Profiles of Key Players
  • 12.3.1 Air Liquide S.A
    • 12.3.1.1 Company Overview
    • 12.3.1.2 Product Portfolio
    • 12.3.1.3 Financials
    • 12.3.1.4 SWOT Analysis
  • 12.3.2 Bellerophon Therapeutics
    • 12.3.2.1 Company Overview
    • 12.3.2.2 Product Portfolio
    • 12.3.2.3 Financials
  • 12.3.3 Beyond Air Inc.
    • 12.3.3.1 Company Overview
    • 12.3.3.2 Product Portfolio
    • 12.3.3.3 Financials
  • 12.3.4 Linde plc
    • 12.3.4.1 Company Overview
    • 12.3.4.2 Product Portfolio
    • 12.3.4.3 Financials
  • 12.3.5 Mallinckrodt plc
    • 12.3.5.1 Company Overview
    • 12.3.5.2 Product Portfolio
    • 12.3.5.3 Financials
  • 12.3.6 Merck KGaA
    • 12.3.6.1 Company Overview
    • 12.3.6.2 Product Portfolio
    • 12.3.6.3 Financials
    • 12.3.6.4 SWOT Analysis
  • 12.3.7 Novoteris LLC
    • 12.3.7.1 Company Overview
    • 12.3.7.2 Product Portfolio
  • 12.3.8 Nu-Med Plus
    • 12.3.8.1 Company Overview
    • 12.3.8.2 Product Portfolio
    • 12.3.8.3 Financials
  • 12.3.9 VERO Biotech LLC
    • 12.3.9.1 Company Overview
    • 12.3.9.2 Product Portfolio